EUVIMEDEUVIMED entdecken
Open Access

Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium

Eric S Schafer iD, Teresa Rushing, Kristine R Crews, Colleen Annesley, Susan I Colace, Nicole Kaiser, Lauren Pommert, Laura B Ramsey, Himalee S Sabnis, Kenneth Wong, Bill H Chang, Todd M Cooper und 7 weitere

JNCI: Journal of the National Cancer Institute · 2024

DOI: 10.1093/jnci/djae165 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2024. Verfasst von Eric S Schafer und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA. Hauptthemen laut MEDLINE: Lymphoma, Leukemia, Clinical Trials as Topic. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH Clinical Center, NCI NIH HHS, Higgins Family Charitable Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The National Cancer Institute (NCI) issued a 2021 memorandum adopting the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research (Friends) task force recommendations to broaden clinical study eligibility criteria. They recommended that washout periods be eliminated for most prior cancer therapy and when required to utilize evidence- and/or rationale-based criteria. The Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) consortium responded to this guidance.

Methods

A TACL task force reviewed the consortium’s research portfolio, the relevant literature and guidance documents from ASCO-Friends, NCI, and US Food and Drug Administration to make expert consensus and evidence-based recommendations for modernizing, broadening, and codifying TACL-study washout periods while ensuring consistency with pediatric ethics, and federal regulations. TACL’s screening log was reviewed to estimate the impact that updated washout periods would have on patient inclusivity and recruitment.

Results

Over a 19-year period, 42 (14.6% of all screened ineligible patients [n = 287]) patients were identified as excluded from TACL early phase studies exclusively because of not meeting washout criteria. An additional 6 (2.1%) did not meet washout and at least 1 other exclusion criterion. A new TACL washout guidance document was developed and then adopted for use. Where washout criteria were not eliminated, rationale- and/or evidenced-based criteria were established with citation.

Conclusion

In an effort to reduce unnecessary exclusion from clinical trials, TACL created rationale- and/or evidenced-based washout period standards largely following guidance from the NCI and ASCO-Friends recommendations. These new, expanded eligibility criteria are expected to increase access to TACL clinical trials while maintaining safety and scientific excellence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LymphomaLeukemiaClinical Trials as TopicHumansChildUnited StatesPatient SelectionNational Cancer Institute (U.S.)

Autor:innen und Institutionen

  • Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
  • Texas Children's Cancer and Hematology Center, Texas Children's Hospital, Houston, TX, USA.
  • Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA.
  • Department of Pharmacy and Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN, USA.
  • Seattle Children's Hospital Cancer and Blood Disorders Service, University of Washington School of Medicine, Seattle, WA, USA.
  • Division of Hematology, Oncology and Blood and Marrow Transplant, Nationwide Children's Hospital, Columbus, OH, USA.

ORCID-Profile: Eric S Schafer

Förderung

  • NIH Clinical Center
  • NCI NIH HHS
  • Higgins Family Charitable Foundation
  • Center of Cancer Research
  • Intramural NIH HHS
  • NIH HHS
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Schafer, E. S., Rushing, T., Crews, K. R., Annesley, C., Colace, S. I., Kaiser, N., Pommert, L., Ramsey, L. B., Sabnis, H. S., Wong, K., Chang, B. H., Cooper, T. M., Shah, N. N., Rheingold, S. R., Place, A. E., Chi, Y. Y., Bhojwani, D., Wayne, A. S., & Bernhardt, M. B. (2024). Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae165

Vancouver

Schafer ES, Rushing T, Crews KR, Annesley C, Colace SI, Kaiser N, et al. Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium. JNCI: Journal of the National Cancer Institute. 2024. doi:10.1093/jnci/djae165

BibTeX
@article{Schafer2024,
  author = {Schafer, Eric S and Rushing, Teresa and Crews, Kristine R and Annesley, Colleen and Colace, Susan I and Kaiser, Nicole and Pommert, Lauren and Ramsey, Laura B and Sabnis, Himalee S and Wong, Kenneth and Chang, Bill H and Cooper, Todd M and Shah, Nirali N and Rheingold, Susan R and Place, Andrew E and Chi, Yueh-Yun and Bhojwani, Deepa and Wayne, Alan S and Bernhardt, M Brooke},
  title = {Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2024},
  doi = {10.1093/jnci/djae165}
}
Kostenlos starten →